blood disorder

(R)-PF-04822163 是 PF-04822163 的异构体。PF-04822163 是一种口服选择性 PDE1 抑制剂，可穿过血脑屏障。PF-04822163 可用于研究神经系统疾病，例如注意力缺陷多动障碍 (ADHD) 和帕金森病。

Dextran sulfate sodium salt (MW 4500-5500) 是一种脱水葡萄糖的聚合物，是补体和凝血途径的抑制剂。Dextran sulfate sodium salt (MW 4500-5500) 可作为抗凝剂、抗病毒剂和抗血脂剂。Dextran sulfate sodium salt (MW 4500-5500) 可阻止 HIV-1 病毒吸附到宿主细胞上。Dextran sulfate sodium salt (MW 4500-5500) 可抑制 NK 细胞介导的细胞毒性。Dextran sulfate sodium salt (MW 4500-5500) 可抑制即时血液介导的炎症反应 (IBMIR)。

4-Hydroxyphenylpyruvic acid 是一种苯丙氨酸代谢的中间产物，是一种酶抑制剂。

BPN 0026709（MT-228） 是一种选择性且能穿透血脑屏障的非肌肉肌球蛋白 II 抑制剂。BPN 0026709 通过选择性靶向 NMIIB（KI = 1.5 μM）而非 CMII（KI = 17 μM），显著提高了耐受性，BPN 0026709 在刺激性物质使用障碍的动物模型中显示出持久的疗效。

ZZL-7是一种起效快的抗抑郁药。ZZL-7破坏中缝背核（DRN）神经元一氧化氮合酶（nNOS）和血清素转运蛋白（SERT）之间的相互作用。ZZL-7可以很容易地穿过血脑屏障。ZZL-7在重度抑郁症（MDD）中具有研究价值。

EHMT2-IN-1 is a potent EHMT inhibitor, . Used in the research of blood disorder or cancer.with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.

Orvepitant maleate is an effective, selective, and well-tolerated neurokinin-1 receptor (NK-1) antagonist (pKi: 10.2 for human neurokinin-1 receptor). Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatmen

INI-4001作为一种TLR7/8激动剂，对TLR7和TLR8的EC50值为1.89 μM和4.86 μM。该化合物通过激活TLR7和TLR8促进信号传导及SEAP的产生。INI-4001能有效促进高亲和力特异性芬太尼抗体的生成，阻止芬太尼通过血脑屏障，对阿片类药物使用障碍 (OUD) 患者的抗芬太尼疫苗起到佐剂作用。

Lu AF90103 (Compound 42e) 是 compound 42d 的甲酯前药，具有穿过血脑屏障的能力。Compound 42d 作为 GluN1 GluN2B 复合物的部分激动剂，其功效为 24%，EC50 值为 78 nM。Lu AF90103 在研究神经精神疾病中极为重要。

Droxidopa (L-DOPS)是一种有效的口服活性去甲肾上腺素前体，能透过血脑屏障。Droxidopa 可增加站立血压，改善体位性低血压症状并提高站立能力，常用于研究神经源性体位性低血压（nOH）和替代性多动症 (注意缺陷多动障碍)等疾病 。

Guanfacine-13C,15N3is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD). 1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Nikolic, K., Filipic, S., and Agbaba, D.QSAR study of imidazoline antihypertensive drugsBioorg. Med. Chem.16(15)7134-7140(2008) 3.Scholtysik, G.Pharmacology of guanfacineBr. J. Clin. Pharmacol.10(Suppl 1)21S-24S(1980) 4.Kauser, H., Sahu, S., Kumar, S., et al.Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive declineNeuroscience254110-119(2013)

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy and non-hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

Droxidopa (L-DOPS) hydrochloride 是一种有效的、具有口服活性的去甲肾上腺素前体。Droxidopa hydrochloride 可增加站立血压，改善直立性低血压症状并提高站立能力。Droxidopa hydrochloride 具有研究神经源性直立性低血压（nOH）和替代性多动症 (注意缺陷多动障碍) 的潜力[3]。

UCPH-102 可用于研究阿尔茨海默病、肌萎缩性侧索硬化症、慢性疼痛和强迫症等，具有良好的血脑通透性。UCPH-102 是高度选择性的 EAAT1抑制剂，IC50值为0.43 μM。UCPH-102 还对 T-ALL 细胞表现出特异性的抗增殖作用。

Mu opioid receptor antagonist 5 (compound NAP) 是一种选择性的、能够透过血脑屏障的 μ 阿片受体 (MOR) 拮抗剂 (EC50: 1.14 nM, Ki: 0.37 nM)。Mu opioid receptor antagonist 5 能够用于研究阿片类药物使用障碍 (OUD)。

Mu opioid receptor antagonist 2 (compound 25) 是一种有效的、选择性的、能透过血脑屏障渗透性的μ 阿片受体 (MOR) 拮抗剂 (Ki: 0.37 nM, EC50: 0.44 nM)。Mu opioid receptor antagonist 2 对吗啡表现出明显的中枢神经系统拮抗活性，诱发戒断症状比 Naloxone 小。Mu opioid receptor antagonist 2 能够用于研究阿片类药物使用障碍 (OUD)。

Mu opioid receptor antagonist 3 (compound 26) 是一种有效的、选择性的、能透过血脑屏障渗透性的μ 阿片受体 (MOR) 拮抗剂 (Ki: 0.24 nM, EC50: 0.54 nM)。Mu opioid receptor antagonist 2 对吗啡表现出明显的中枢神经系统拮抗活性，诱发戒断症状比 Naloxone 小。Mu opioid receptor antagonist 2 能够用于研究阿片类药物使用障碍 (OUD)。

Mu opioid receptor antagonist 4 (compound 31) 是一种有效的、选择性的、能透过血脑屏障渗透性的μ 阿片受体 (MOR) 拮抗剂 (Ki: 0.38 nM, EC50: 0.38 nM)。Mu opioid receptor antagonist 2 对吗啡表现出明显的中枢神经系统拮抗活性，诱发戒断症状比 Naloxone 小。Mu opioid receptor antagonist 2 能够用于研究阿片类药物使用障碍 (OUD)。

VU6019650 是一种强效、选择性的M5mAChR 正向拮抗剂 (IC50=36 nM)，能够用于减轻阿片类药物使用障碍 (OUD) 的研究。VU6019650 具有血脑透过性，可能调节中边缘多巴胺能奖赏回路。VU6019650 能够阻断Oxotremorine M iodide 诱导引起的腹侧被盖区中脑 (VTA) 多巴胺神经元的放电速率的增加。

SR 142948 dihydrochloride是一种口服活性高、选择性强的非肽类神经降压素受体(NT)拮抗剂，其在h-NTR1-CHO细胞、HT-29细胞和成年大鼠脑中IC50分别为1.19 nM、0.32 nM、3.96 nM。在HT-29细胞中，该化合物能够有效拮抗NT诱导的肌醇单磷酸盐形成，IC50为3.9 nM。此外，SR 142948 dihydrochloride在体内能够阻断NT诱导的体温下降、镇痛和转向行为，且具有良好的血脑屏障通透性，适用于精神疾病研究。

PKR activator 4 (example 7A) 是一种高效的丙酮酸激酶 R (pyruvate kinase R (PKR)) 激活剂，展现出研究血液疾病的潜力。

Dazukibart 是一种源自小鼠的人源化IgG1κ抗IFNB1单克隆抗体，正在被研究作为皮肌炎的潜在治疗方法。皮肌炎是一种复杂的自身免疫性疾病，其病理特征为患者血液、皮肤和肌肉组织中干扰素（IFN）诱导基因的显著过表达。

3β,5α,6β-Trihydroxycholanic acid, a metabolite derived from 5α,6β-dihydroxycholestanol, exhibits elevated levels in dried blood spots of patients diagnosed with Niemann-Pick disease type C, a neurodegenerative disorder characterized by the accumulation of cholesterol and sphingolipids in lysosomes.